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A B S T R A C T
Proteus mirabilis is a common pathogen in urinary tract infections (UTIs). There is no vaccine against P. mirabilis,
thus a novel multi-peptide vaccine of MrpA, UcaA and Pta factors of P. mirabilis we designed and a mice model
was used to evaluate its eﬃcacy in combination with AddaVax adjuvant. According to the bioinformatics studies,
7 fragments of MrpA (31–75, 112–146), UcaA (68–117, 132–156) and Pta (210–265, 340–400, 496–570) with B
and T cell epitope regions were selected for fusion construction. Mice subcutaneously vaccinated with the fusion
MrpA.Pta.UcaA induced a signiﬁcant increase in serum and mucosal IgG and IgA responses. The fusion also
showed a signiﬁcant induction in cellular responses (Th1 and Th2). The addition of AddaVax to fusion and the
mixture of MrpA, UcaA, and Pta (MUP) improved the humoral and cellular responses, especially the IgG2a and
IFN-γ (Th1 responses) levels. Fusion with and without AddaVax and MUP+AddaVax could maintain signiﬁcant
humoral responses until 6 months after the ﬁrst vaccine dose. All vaccine combinations with and without ad-
juvant showed high eﬀectiveness in the protection of the bladder and kidney against experimental UTI; this
could be attributed to the signiﬁcant humoral and cellular responses. The present study suggests that the
AddaVax-based vaccine formulations especially the fusion Pta.MrpA.UcaA admixed with AddaVax as potential
vaccine candidates for protection against P. mirabilis. Furthermore, AddaVax could be considered as an eﬀective
adjuvant in designing other vaccines against UTI pathogens.
1. Introduction
Urinary tract infections (UTIs) are among the most common in-
fectious diseases that occur in both community and hospital environ-
ments. Proteus mirabilis is recognized as a common pathogen in the
catheter-associated UTIs (CAUTIs), nosocomial UTIs, and complicated
UTIs (Adams-Sapper et al., 2012; Zunino et al., 2007). Among the
known virulence factors of P. mirabilis, the mannose-resistant Proteus-
like ﬁmbriae (MR/P) and uroepithelial cell adhesin (UCA, newly re-
named as non-agglutinating ﬁmbriae) play important roles in the
binding and colonization of the urinary epithelial cells. MrpA and UcaA
constitute the major subunits of MR/P and UCA ﬁmbriae, respectively
in P. mirabilis (Pellegrino et al., 2003; Scavone et al., 2015). Further-
more, another virulence factor of P. mirabilis which is characterized by
its cytotoxic role in the formation of pore in the epithelial cells of the
host is Proteus toxic agglutinin (Pta) (Alamuri et al., 2009).
The majority of UTIs are always treated with the administration of
antibiotics, but the emergence of multi-drug resistant strains is be-
coming a major problem in the treatment of UTIs. Furthermore, the
deﬁcient response to antibiotics in complicated UTIs, recurrent UTIs,
and the ability of P. mirabilis to cause acute pyelonephritis, stone for-
mation, bacteremia, and sepsis are other major challenges (Armbruster
and Mobley, 2012; Scavone et al., 2011). These challenges show the
need to work on the development of vaccines for the prevention of UTIs
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caused by P. mirabilis (Alamuri et al., 2009).
The pathogenesis of bacteria does not rely on a particular virulence
factor, thus in most cases, vaccination with an antigen alone could not
elicit a protective immune response (Skwarczynski and Toth, 2016). In
this regard, to induce considerable immune responses, the use of multi-
subunit or multi-peptide approaches is suggested. A multi-epitope or
peptide-based vaccine has the advantages of delivering high doses of
antigens for developing the immune responses while avoiding poten-
tially hazardous and undesirable side eﬀects for killed and attenuated
vaccines (Li et al., 2012; Purcell et al., 2007).
To date, ﬂagellin, killed P. mirabilis strain, puriﬁed MR/P ﬁmbriae,
recombinant MrpH and Pta, MrpA expressed in Lactococcus lactis and
Salmonella typhimurium, and a complex of recombinant MrpA, UcaA and
PmfA were previously considered as vaccine candidates against P.
mirabilis (Alamuri et al., 2009; Habibi et al., 2015a; Li et al., 2004;
Pellegrino et al., 2003; Scavone et al., 2007; Scavone et al., 2004;
Scavone et al., 2011). Limitations such as the phase variation of MR/P
(and MrpH) and ﬂagellin suggest that these proteins have been used in
combination with other proteins (Alamuri et al., 2009). Presently, no
multi-epitope or peptide based vaccine has been developed against P.
mirabilis (Scavone et al., 2004), whereas P. mirabilis strains contain
diﬀerent virulence factors which could be applied in a multi-peptide
vaccine. These selected peptides should preferentially be surface ex-
posed, be highly antigenic, have important role in pathogenicity, and
contain conserved sequences among P. mirabilis strains (Haugen et al.,
2007; Wieser et al., 2010). The highly conserved nature of MrpA, UcaA
and Pta components and their important roles in cystitis and pyelone-
phritis make them promising candidates against UTI by P. mirabilis
(Pellegrino et al., 2003; Scavone et al., 2015).
Thus, the aim of the present study was to design a novel multi-
peptide vaccine containing both T and B-cell epitopes of MrpA, UcaA
and Pta proteins of P. mirabilis. Then, the immunogenicity and eﬃcacy
of the induced humoral and cellular responses by the constructed fusion
protein with and without AddaVax adjuvant was evaluated in the mice
model.
2. Materials and methods
2.1. Sequence, databases and construct design
The full-length protein sequences of MrpA (GenBank: CAA83633.1),
UcaA (GenBank: CAA54703.1) and Pta passenger domain (GenBank:
CAR44626.1) of P. mirabilis HI4320 strain were obtained from the NCBI
database (http://www.ncbi.nlm.nih.gov/protein/). BLASTP was used
to recognize common and conserved antigenic fragments among these
sequences (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins).
The location of signal peptide was predicted using SignalP (http://
www.cbs.dtu.dk/services/SignalP) and PREDTMBB was used to de-
termine the extracellular regions of Pta passenger domain (http://
bioinformatics.biol.uoa.gr/PRED-TMBB/). All the protein sequences
were analyzed to identify the best fragments containing combined B
and T cell epitopes. The selected antigenic fragments were fused to-
gether by a repeat of the GPGPG (Gly-Pro-Gly-Pro-Gly) linker. Finally,
the fused antigen was characterized using the VaxiJen 2.0 server
(http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html).
2.2. Prediction of B- and T- cell epitopes for fusion construction
Protein sequences of MrpA, UcaA and Pta passenger domain were
used to predict linear B-cell epitopes (20mers) using ABCpred (http://
www.imtech.res.in/raghava/abcpred/), BCPred (http://ailab.ist.psu.
edu/bcpreds/predict.html) (EL-Manzalawy et al., 2008) and BepiPred
(http://www.cbs.dtu.dk/services/Bepipred/) servers. The B cell epi-
topes were predicted using three servers with cutoﬀ score> 0.8.
Propred-1 (47 MHC Class-I alleles) (http://www.imtech.res.in/
raghava/propred1/) (Singh and Raghava, 2003), Propred (51 MHC
Class-II alleles) (http://www.imtech.res.in/raghava/propred/) (Singh
and Raghava, 2001) and MHCPred (http://www.ddg-pharmfac.net/
mhcpred/MHCPred/) (Guan et al., 2003) servers were used to identify
T-cell epitopes containing B-cell epitope sequences, which could in-
teract with both major histocompatibility molecules (MHC) class I & II
with the highest score (more than 15) and further analyzed with Vax-
iJen (threshold>0.4). Among the diﬀerent haplotypes of MHC in mice,
those containing H2d haplotypes were selected. These alleles contained
I-Ad and I-Ed of class II as well as H2-Kd, H2-Ld, H2-Dd of class I MHC
(Hood et al., 1983). The sequences of peptides binding to various mice
MHC alleles were obtained from the RANKPEP (http://bio.dfci.harvard.
edu/RANKPEP/) and SYFPEITHI databases. In RANKPEP, MHC-II re-
stricted epitopes with high score were predicted at 4–6% binding
threshold. In RANKPEP, MHC-I restricted epitopes with signiﬁcant
score were predicted at 2–3% binding threshold. Score> 20 was as-
sumed as strong binding in the SYFPEITHI database.
2.3. Cloning, expression, and protein puriﬁcation
The designed fusion gene consisting of mrpA, ucaA and pta epitopes
was codon optimized and synthesized by Biomatik Company (Canada)
and then cloned within the expression vector pET28a (Novagen, USA).
Furthermore, the cloning of full-length mrpA (175 aa) and ucaA (180
aa) and also the passenger domain of the pta (524 aa) was performed in
accordance with previous protocols (Asadi et al., 2012). Brieﬂy, these
genes in P. mirabilis HI4320 strain were ampliﬁed using Polymerase
Chain Reaction (PCR), having primers designed with the restriction
enzymes NcoI and HindIII. Thereafter, the digested fragments were
cloned into the digested pET28a vector and transformed into the
competent E. coli BL21/plysS host (Invitrogen, USA). Positive clones
were conﬁrmed by PCR, double digestion and sequencing. Synthesis of
recombinant proteins fusion, MrpA, UcaA, and Pta alone was induced
by adding diﬀerent concentrations of isopropyl-beta-thio galactopyr-
anoside (IPTG) in diﬀerent concentrations (Asadi et al., 2012; Habibi
et al., 2017). Then, the protein expression was assessed by 15% Sodium
Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and
conﬁrmed by Western blotting using monoclonal HRP-conjugated His-
speciﬁc antibody (Sigma, USA). Brieﬂy, after separation of recombinant
proteins on a SDS-PAGE gel and their blotting into a nitrocellulose
membrane, the membranes were blocked and the conjugated His-spe-
ciﬁc antibody was added in 1:1000 dilution to develop by DAB+H2O2
substrate (Asadi et al., 2012).
In the next stage, the expressed proteins were puriﬁed by His tag
aﬃnity chromatography on Ni-NTA column (Qiagen) with a dena-
turation system and by applying triton X-114 for removing the lipo-
polysaccharide (LPS) of the recombinant proteins (Habibi et al.,
2015b). The LPS level of the puriﬁed proteins was measured using the
chromogenic Limulus Amebocyte Lysate test (LAL), according to the
manufacturer’s protocol (Lonza). Then, the puriﬁed proteins were dia-
lyzed against diﬀerent concentrations of urea and the ﬁnal concentra-
tions were measured using Bradford assay with concentrated Bradford
solution.
2.4. Animals
Female BALB/c mice of 6–8 weeks old were purchased from the
Pasteur Institute of Iran and all the animal tests were performed ac-
cording to the European Communities Council directive of 24
November 1986 (86/609/EEC).
2.5. Subcutaneous immunization of mice
The mice were divided into ﬁve groups of each 15. The injections
were given three times within 2-week intervals (on days 0, 14, and 28)
from a subcutaneous (S.C.) route with 50 μg of fusion protein alone,
fusion protein admixed with AddaVax (50 μg protein+ 50 μl adjuvant),
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and a combination of puriﬁed proteins MrpA, Pta and Uca with
AddaVax (17.5 μg of each protein+ 50 μl adjuvant) (Habibi et al.,
2015a). AddaVax was prepared following the manufacturer’s instruc-
tions (InvivoGen). The control groups (negative controls) were injected
with AddaVax or PBS alone. Sera were collected after each injection
until 180 days to determine the humoral responses. The vaccinated
mice were consequently used for cytokine and challenge experiments.
2.6. Antibody assay in the immunized mice
Antigen-speciﬁc serum and urine responses including total IgG, IgA
and IgG isotypes (IgG1 and IgG2a) were determined by standard en-
zyme-linked immunosorbent assay (ELISA). Brieﬂy, the ELISA 96-well
plates (Greiner, Germany) were coated with puriﬁed proteins MrpA,
UcaA, and Pta (10 μg/ml in PBS) and incubated overnight. The
boundless positions in plates were blocked with 3% bovine serum al-
bumin (BSA) and the plates were incubated with twofold serial dilu-
tions of immune serum (1:50–1:6400) and mucosal samples (undiluted,
1:5 and 1:10) in 1% BSA. Thereafter, HPR-conjugated goat anti-mouse
IgG, IgG1, IgG2a and IgA (Sigma, USA) were used as secondary anti-
bodies. The plates were incubated with the TMB substrate to visualize
antibody reactivity at 450 nm using an ELISA reader (Habibi et al.,
2015a; Li et al., 2004).
2.7. Cytokine assay in the vaccinated mice
Six mice from each group were sacriﬁced two weeks after the last
vaccine dose to evaluate the production of interferon-γ (IFN-γ), inter-
leukin-4 (IL-4) and IL-17 cytokines using monoclonal antibodies against
the cytokines in the supernatant of cultured splenocytes. Brieﬂy, the
spleen cells (3× 105 cell/well) were cultured in 24-well microtiter
plates (Greiner, Germany) under sterile conditions and incubated with
and without 10 μg/ml of ﬁltered proteins MrpA, UcaA, and Pta to col-
lect the supernatants after 72 h of incubation. Finally, the cytokine le-
vels in the supernatants were measured using the Mouse DuoSet ELISA
kit following the manufacturer’s instructions (R&D Systems, USA)
(Habibi et al., 2015a).
2.8. Urinary tract infection model in mice
The protection eﬀectiveness of induced immune responses was as-
sayed in the vaccinated groups using the bladder challenge model. This
model was optimized in our animal facility with naïve mice to achieve
the best time period for the challenge assay. Brieﬂy, in this ascending
UTI model, six mice in each vaccinated group were anesthetized; their
bladders were emptied with gentle pressure and challenged transur-
ethrally with 1×108 cfu/ml of P. mirabilis HI4320 strain using sterile
polyethylene catheter (Habibi et al., 2015a). One week after
inoculation of P. mirabilis, the mice were sacriﬁced and their homo-
genized bladders and kidneys were cultured in diﬀerent dilutions to
determine the bacterial loads in these plates.
2.9. Statistical analysis
Statistical analysis of the antibody and cellular immune responses
were performed using One Way Analysis of Variance (ANOVA), Student
t-test, and Tukey HSD tests. Challenge results were analyzed in diﬀerent
groups with Version 6 Prism (GraphPad) program, which compare the
median results obtained in diﬀerent groups with the Kruskal-Wallis test
(Dunn’s multiple comparison tests). In all statistical analyses, the value
of p < 0.05 was considered as the statistical index.
3. Results
3.1. Deﬁning the B-cell and T-cell epitopes of proteins
MrpA, UcaA and N-terminal passenger domain of the Pta protein
were selected for the construction of a fusion gene. The topology of the
Pta passenger domain was predicted using PRED-TMBB. Graphical po-
sition of the transmembrane ß strands and the location of the peri-
plasmic and extracellular loops are mentioned in Fig. S1 in the
Supplementary Material. Then, B-cell epitopes in each antigen were
predicted by ABCpred, BCPred and BepiPred servers. Generally, 20-mer
linear epitopes with scores> 0.8 in ABCpred and BCpreds were se-
lected from MrpA, UcaA and Pta antigens and these data are shown in
Table 1 in the Supplementary Material. To screen the T-cell epitopes,
Propred-I, Propred, and MHCPred were used and data about the T-cell
predictions of antigens are shown in Table 2 in the Supplementary
Material. Finally, after analyzing the results, 7 fragments were selected
including: MrpA (31–75, 112–146), UcaA (68–117, 132–152), and Pta
passenger domain (210–265, 340–400, 496–570) with B and T cell
epitope regions expected to be strong antigenic fragments. These frag-
ments were sequentially connected by the GPGPG linker to form a fu-
sion protein, which contained 373 amino acids. A schematic diagram of
the protein domain structures with linkers is shown in Fig. 1. Further-
more, the composition of the designed multi-peptide vaccine candidate
along with their various parameters is shown in Table 1.
3.2. Cloning, expression, and protein puriﬁcation
In this study, a fusion gene of the selected epitopes of MrpA, UcaA
and Pta was constructed and cloned into the pET28a vector.
Subsequently, mrpA, ucaA and pta genes were cloned successfully into
the vector and conﬁrmed by diﬀerent methods. Fusion pta.mrpA.ucaA
and the genes alone were successfully expressed in E. coli BL21/plysS
and puriﬁed using a nickel chromatography column. As shown in
Fig. 1. Schematic representation construct consists of MrpA, UcaA and Pta epitopes of the P. mirabilis HI4320 strain linked together with linkers.
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Fig. 2A, the SDS-PAGE results of the fusion, MrpA, UcaA, and Pta
puriﬁed proteins showed that the expressed proteins had molecular
weights of approximately 44, 18, 22, and 60 kDa conﬁrmed by the use
of Western blot (Fig. 2B). The endotoxin level of the puriﬁed and dia-
lyzed proteins was less than 1 EU/ml measured using the LAL test.
3.3. Assessment of total IgG and longevity of responses
At ﬁrst, the induced IgG responses were assayed in diﬀerent dilu-
tions of serum (1:50–1:6400) obtained 2-weeks after the last vaccine
dose. As shown in Fig. 3A–C, lower serum dilutions could not diﬀer-
entiate between the IgG levels of mice groups, while the dilution of
1:800 could diﬀerentiate between the IgG levels of the mice groups. It
was observed that IgG responses against Pta (A), MrpA (B) and UcaA
(C) in all vaccine combinations with and without AddaVax were sig-
niﬁcantly enhanced as compared to the control mice which received the
AddaVax or PBS (p < 0.001). Furthermore, the addition of AddaVax to
fusion Pta.MrpA.UcaA (p < 0.05) or the mixture of MrpA, UcaA and
Pta (MUP) (p < 0.01) resulted in a signiﬁcant increase of IgG re-
sponses than fusion protein alone (Fig. 3). However, there was no sig-
niﬁcant diﬀerence between the IgG responses of the Fusion+AddaVax
and MUP+AddaVax groups (p > 0.05).
The longevity results of humoral responses showed that anti-Pta,
MrpA and UcaA responses were increased after the ﬁrst vaccine dose in
mice received the fusion, fusion+AddaVax and MUP+AddaVax until
day 110, and the immune responses were maintained in a steady state
until day 180 after the ﬁrst immunization (Fig. 4A–C). Furthermore, a
signiﬁcant diﬀerence was observed between the induced responses by
the vaccine formulations with control groups after the second vaccine
dose, which was maintained throughout the study (p < 0.001). The
signiﬁcant diﬀerence between IgG responses of the Fusion alone with
Fusion+AddaVax and MUP+AddaVax groups was found after the
third vaccination until day 180 (p < 0.05).
3.4. Measurement of isotype antibodies in serum
The isotype antibodies IgG1, IgG2a and IgA were measured in serum
2-weeks after the third vaccination. As shown in Fig. 5A–C, all vaccine
combinations with and without adjuvant were able to induce signiﬁcant
IgG1 and IgG2a responses against antigens Pta (A), MrpA (B) and UcaA
(C) as compared to the control mice (p < 0.01). The addition of Ad-
daVax to the vaccine combinations of fusion alone (p < 0.01) and the
mixture of Pta, MrpA and UcaA signiﬁcantly boosted the IgG2a re-
sponses (p < 0.02), whereas AddaVax could not signiﬁcantly enhance
the IgG1 responses of these combinations (p > 0.05) (Fig. 5A–C). The
IgG1/IgG2a ratio in mice inoculated with AddaVax formulations were
signiﬁcantly reduced as compared to mice immunized without Ad-
daVax (p < 0.05) (Fig. 5A–C).
All the vaccine combinations developed a signiﬁcant anti-IgA serum
response as compared to mice injected with AddaVax or PBS
(p < 0.001) (Fig. 5D). Similar to the IgG1 responses, AddaVax could
signiﬁcantly improve the IgA responses of fusion and MUP vaccine
combinations (p < 0.01).
3.5. Mucosal responses in the mice groups
According to the role of mucosal responses in the prevention of
UTIs, the induced mucosal responses were measured in the urine
samples obtained after the last immunization dose. As shown in Table 2,
fusion with and without AddaVax and MUP+AddaVax signiﬁcantly
showed higher mucosal IgG and IgA levels compared to the control
mice (p < 0.05). AddaVax was also observed to signiﬁcantly increase
the mucosal IgG responses of all antigens than the fusion alone
(p < 0.05), whereas AddaVax was only able to signiﬁcantly increase
the mucosal anti-UcaA IgA of mice vaccinated with the MUP mixture
than mice immunized with fusion alone (p=0.045) (Table 2). Fur-
thermore, there was no signiﬁcant diﬀerence in the induced IgG or IgA
mucosal responses between fusion+AddaVax and MUP+AddaVax
vaccine combinations (p > 0.05).
Table 1
Composition of the designed multi-peptide vaccine candidate along with their various parameters.




No. of B cell
epitopes
No. of putative epitopes
(Human)
No. of putative epitopes
(mice)
VaxiJen scores
MHC-I MHC-II MHC-I MHC-II
MrpA 1 31–75 45 4 4 3 1 5 0.4559
2 112–146 35 1 3 3 1 1
UcaA 1 68–117 50 2 1 2 1 1 1.105
2 132–152 21 1 1 1 1 1 1.3424
Pta 1 210–265 56 4 3 5 2 4 0.8244
2 340–400 61 1 2 9 1 5 0.5327
3 496–570 75 4 3 7 2 7 0.7046
Fig. 2. Evaluation of the puriﬁed proteins. The re-
combinant proteins MrpA, UcaA, Pta and fusion were
puriﬁed using the nickel resins and evaluated by (A)
SDS-PAGE and (B) Western blot using the His-speciﬁc
monoclonal antibody. Lane 1: UcaA; Lane 2: Fusion;
Lane 3: Pta; Lane 4: MrpA; and MW: protein marker
(prestained and non-prestained for SDS-PAGE and
Western blot, respectively).
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3.6. Cytokine responses in the immunized mice
In this study, the measurement of cytokines levels was done to de-
termine the cell mediated immunity (CMI) induced by the vaccine
combinations. The secretion of IFN-γ, IL-4 and IL-17 in the splenocytes
of all mice groups stimulated with Pta, MrpA and UcaA was increased
compared to the control mice (p < 0.05) (Fig. 6). The ﬁndings showed
that a higher level of IFN-γ production in mice groups received
MUP+AddaVax and fusion+AddaVax compared to mice injected
with fusion alone (p < 0.05), whereas the diﬀerence between the IFN-
γ levels of mice groups MUP+AddaVax and fusion+AddaVax was not
statistically signiﬁcant (p > 0.05) (Fig. 6A). Although, AddaVax was
found to enhance the IL-4 secretion of the vaccine combinations, these
increases were not statistically signiﬁcant as compared to the fusion
alone (p > 0.05) (Fig. 6B). Interestingly, immunization with fu-
sion+AddaVax combination resulted in signiﬁcantly higher IL-17 le-
vels compared to the fusion protein alone (p < 0.001) and
MUP+AddaVax group (p < 0.01). In addition, there was no sig-
niﬁcant diﬀerence between the levels of IL-17 in comparison of
MUP+AddaVax group with fusion alone (p > 0.05) (Fig. 6C). The
addition of AddaVax to the fusion alone group could not signiﬁcantly
enhance the IFN-γ/IL-4 ratio (p > 0.05). Also, no signiﬁcant diﬀerence
was observed between the IFN-γ/IL-4 ratio in Pta or UcaA-stimulated
splenocytes of mice vaccinated with fusion alone and MUP+AddaVax
(p > 0.05) (Fig. 6A), whereas the ratio in MrpA-stimulated splenocytes
of mice immunized with MUP+AddaVax signiﬁcantly reduced com-
pared to mice injected with fusion protein alone (p < 0.05).
3.7. Results of bladder challenge in the mice model
In mice, the eﬃcacy of protective immune responses against ex-
perimental UTI was evaluated by bladder challenge. After optimization
of challenge with P. mirabilis HI4320 strain, the naïve mice were ob-
served to be colonized with about 107 and 105 cfu of bacteria in the
bladder and kidneys, respectively after 1 week post bladder challenge.
It was also observed that all vaccine combinations with and without
AddaVax reduced the load of P. mirabilis to about 103–106 CFU in both
the bladders and kidneys of mice as compared to the control mice
(Fig. 7). The addition of AddaVax to fusion vaccine formulation de-
creased the mean of bacteria from 219 to 119 in the bladder and from
1425 to 52 in kidneys, but these reductions were not statistically sig-
niﬁcant (p > 0.05) (Fig. 7). Furthermore, no signiﬁcant diﬀerence was
observed between the mean and median of bacteria recovered from the
bladders and kidneys of mice vaccinated with MUP+AddaVax as
compared to the fusion alone and fusion+AddaVax (p > 0.05)
(Fig. 7).
4. Discussion
Proteus mirabilis strains cause UTIs, particularly in patients who are
obligated to use urinary catheters during their treatment period
(Jacobsen and Shirtliﬀ, 2011; Scavone et al., 2011). Despite the im-
portance of P. mirabilis and emergence of multi-drug resistant strains,
there are several vaccine candidates based on the monovalent factors or
fusion proteins tested by our research team (Habibi et al., 2015a;
Habibi et al., 2015b) and by others (Alamuri et al., 2009; Li et al., 2004;
Fig. 3. Measurement of the serum IgG responses. Mice were immunized with the fusion, fusion+AddaVax and the mixture of MrpA, UcaA and Pta (MUP) with AddaVax and IgG
responses were measured 2-weeks after the third vaccine dose. The control groups received the AddaVax or PBS alone. Results are mean and standard errors of three independent
experiments at diﬀerent serum dilutions (1:50 to 1:6400). The single asterisks show statistical signiﬁcance of IgG responses of all groups over the control mice, and AddaVax combinations
than fusion alone in serum dilution 1:800.
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Scavone et al., 2007; Scavone et al., 2004; Scavone et al., 2011) against
P. mirabilis UTIs in mice model. These researches are ongoing to achieve
eﬀective vaccine combinations against P. mirabilis UTIs. Since, the im-
portance of virulence factors MrpA, UcaA, and Pta among P. mirabilis
strains and also their consideration as promising vaccine candidates, a
novel multi-peptide vaccine of these factors was designed against P.
mirabilis that might be more likely to develop as an eﬀective vaccine
against P. mirabilis UTIs (Nielubowicz et al., 2008; Wieser et al., 2010).
Diﬀerent bioinformatics approaches have been employed for the pre-
diction of B- and T- cell epitopes of MrpA, UcaA and Pta antigens in a
fusion form to increase the chance of inducing protective immunity
against P. mirabilis, because of the possible role of B-cell (humoral re-
sponse) and T-cell (cellular response) in protection against UTIs
(Thumbikat et al., 2009). The selected epitopes were found to be highly
conserved among diﬀerent P. mirabilis strains. Following the im-
portance of linkers for attaching the multi-domain proteins and accu-
rate function (Arai et al., 2001), these selected domains were fused
together by a linker such that the epitopes could function in-
dependently and the formation of new epitopes could be avoided (Yano
et al., 2005).
Despite the advantages of peptide-based vaccines, the use of ad-
juvants is often required to enhance the immune response against an-
tigens and shift the responses to a desired direction (Skwarczynski and
Toth, 2016). AddaVax adjuvant is a squalene-based oil-in-water nano
emulsion with a formulation similar to the MF59 adjuvant (Calabro
et al., 2013). Little studies about the eﬃcacy of AddaVax showed its
ability to induce both humoral (Th2) and cellular (Th1) responses
against antigens. Thus, AddaVax was used as an adjuvant to increase
the chance of activation of both B and T cells in eradicating the
superﬁcial and intracellular reservoirs of P. mirabilis. Furthermore, to
the best of our knowledge this is the ﬁrst report in which AddaVax has
been used in combination with a vaccine candidate against UTI.
According to our previous experiments (Asadi Karam et al., 2013;
Habibi et al., 2015a; Karam et al., 2013; Karam et al., 2016) and the
fact that the multi-peptide vaccine candidate was designed for the ﬁrst
time, its eﬀectiveness in S.C. route of immunization was evaluated.
Furthermore, by using AddaVax as a systemic adjuvant in previous
studies (Mitchell et al., 2016; Smet et al., 2016), it was rational to use
the S.C. route in this study.
In this study, it was found that antigens Pta, MrpA and UcA in fusion
and non-fusion form could elicit serum IgA, IgG1 (Th2) and IgG2a
(Th1) responses without the use of adjuvant. In other studies
(Pellegrino et al., 2003; Scavone et al., 2004), the S.C. or intranasal
(I.N.) administration of MrpA and UcaA alone resulted in the produc-
tion of serum IgG, whereas the serum IgA was only induced in the I.N.
route. A comparison of the vaccine formulations with the combinations
in our recent studies (Habibi et al., 2015a; Habibi et al., 2015b) showed
the higher potential of the present candidates in inducing systemic
humoral responses compared to previous candidates. The data also
showed that the use of AddaVax could improve the serum IgA, IgG and
IgG2a responses of antigens in both fusion and combined forms. Smet
et al. (2016) also showed the potential of AddaVax in the induction of
high titers of both IgG1 and IgG2a against the synthetic mycolates from
Mycobacterium tuberculosis antigens.
As the importance of long-lasting antibodies and generation of long-
lived B cell memory in prevention of recurrent UTIs (Brumbaugh et al.,
2013), the longevity of humoral responses was assessed until 6 months
when all vaccine combinations could maintain high levels of the IgG
Fig. 4. Evaluation of the longevity of serum IgG responses. Mice were immunized and the longevity of (A) anti-Pta, (B) MrpA and (C) UcaA responses was measured. Results are expressed
as mean and standard errors of three independent experiments from 3 mice per groups at serum dilution 1:800.
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responses and this ﬁnding was one of the most important advantages of
these designed vaccines. The IgG responses in mice vaccinated with
fusion without adjuvant were observed to be maintained until the end
of this assay, whereas in our recent study (Habibi et al., 2015a), anti-
MrpH responses in fusion MrpH.FimH tend to decline 12 weeks after
the ﬁrst vaccine dose. This point shows the advantage of the designed
multi-peptide vaccine than the previous candidates.
The present study and our recent ﬁndings (Habibi et al., 2015a;
Karam et al., 2016) demonstrated that systemic immunization of mice
could induce mucosal responses and adjuvant improved these re-
sponses. Pellegrino et al. (2003) could not detect the anti-IgG or IgA
mucosal responses in S.C. immunization of mice with MrpA or UcaA,
whereas Scavone et al. (2004) showed the ability of MrpA or UcaA in
the induction of mucosal responses in I.N. route.
In the present study, the vaccine combinations induced the pro-
duction of both IFN-γ and IL-4 as the indication of Th1 and Th2 re-
sponses, respectively. A mixture of Th1/2 response could be due to the
recruitment of the antigen presenting cells (APCs) and T CD4+ cells
which resulted in high levels of Th1 and Th2 cytokines production.
Scavone et al. (2007) also reported that MrpA expressed by L. lactis
produced a signiﬁcant IFN-γ levels that was several folds less than the
vaccine formulations of the present study. Furthermore, the ability of
the fusion and MUP combination in inducing the IFN-γ was signiﬁcantly
higher than our previous candidates against P. mirabilis (Habibi et al.,
2015a) and it showed the other advantage of the present vaccine for-
mulations than that of the previous vaccine candidates.
The ﬁndings of the present study similar to the report of Wu et al.
(2015) showed that AddaVax induced a mixture of Th1 (IgG2a and IFN-
γ) and Th2 (IgG1 and IL-4) responses against antigens. The comparison
of the MPL-vaccine formulations in our recent studies with the AddaVax
combinations in the present study showed the ability of AddaVax in
inducing cytokines Th1 and Th2 when compared with MPL adjuvant
(Habibi et al., 2015a; Habibi et al., 2015b). Based on the IgG1/IgG2a
ratio, it can be concluded that AddaVax tends to shift the immune re-
sponses preferentially towards Th1 direction which has the advantage
to eradicate the intracellular reservoirs of P. mirabilis. Also, other stu-
dies have shown the potential of AddaVax in shifting the responses
toward Th1 or Th2 direction (Mitchell et al., 2016; Umthong et al.,
2015; Wei et al., 2017; Wu et al., 2015). Wei et al. (2017) and Umthong
et al. (2015) showed that AddaVax generated the Th1 responses against
antigens from Ascaris suum and Leptospirosis, respectively. The poten-
tial of AddaVax in eliciting the Th2-type IgG1 antibody response was
observed against antigens of Mycoplasma hyopneumoniae (de Oliveira
et al., 2017) and Plasmodium falciparum (Mitchell et al., 2016). These
Fig. 5. Evaluation of isotype antibodies in the mice sera. The mice were immunized and (A) anti-Pta IgG1 and IgG2a, (B) anti-MrpA IgG1 and IgG2a, (C) anti-UcaA IgG1 and IgG2a and
(D) IgA responses were assessed in the immunized mice. Single asterisk shows statistical signiﬁcance of IgA responses over the control mice, and double asterisks show statistical
signiﬁcance of IgA over Fusion and control groups. The results are the average of three independent experiments. Bars represent mean ± S.D. from 12 mice per groups at serum dilution
1:800.
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Table 2
Mesurement of the mucosal responses in the immunized mice. Two weeks after the third vaccine dose, (A) IgG and (B) IgA levels were evaluated in the urine samples. Single asterisks
show statistical signiﬁcance of IgG and IgA over the control mice, and double asterisks indicate statistical signiﬁcance of IgG and IgA over fusion group and control mice in dilution 1:5 of
urine. The results are the average of O.D. three independent experiments from 12 mice per groups at diﬀerent dilutions of urine.
(A)
Anti-Pta IgG Anti-MrpA IgG Anti-Uca IgG
Groups undiluted 1:5 1:10 undiluted 1:5 1:10 undiluted 1:5 1:10
Fusion 1.35 1.3* 0.65 1 0.8* 0.5 1.1 0.63* 0.43
Fusion+AddaVax 2.5 2.32** 1.5 1.3 1.4** 0.7 1.31 1.12** 0.71
MUP+AddaVax 2.1 1.92** 0.9 1.45 1.61** 0.9 1.48 1.41** 0.79
AddaVax 0.95 0.46 0.41 0.91 0.4 0.35 0.73 0.36 0.32
PBS 0.85 0.33 0.28 0.75 0.31 0.28 0.82 0.28 0.26
(B)
Anti-Pta IgA Anti-MrpA IgA Anti-Uca IgA
Groups undiluted 1:5 1:10 undiluted 1:5 1:10 undiluted 1:5 1:10
Fusion 1.74 1.45* 0.63 1.66 1.3* 0.75 1.47 1.32* 0.67
Fusion+AddaVax 1.55 1.34* 0.57 1.7 1.23* 0.83 1.83 1.42* 0.81
MUP+AddaVax 1.2 1.16* 0.6 1.57 1.53* 1.11 1.96 1.74** 1.15
AddaVax 0.88 0.38 0.32 0.75 0.41 0.38 0.82 0.4 0.38
PBS 0.85 0.29 0.27 0.69 0.31 0.3 0.75 0.39 0.38
Fig. 6. Evaluation of the cytokine responses in the immunized mice. The splenocytes of each mice group were stimulated with Pta, MrpA and UcaA antigens and the supernanants were
analyzed for secretion of (A) IFN-γ, (B) IL-4 and (C) IL-17 levels. The single asterisks show statistical signiﬁcance of IFN-γ, IL-4 or IL-17 over control mice (p < 0.05). Double asterisks
indicate statistical signiﬁcance of IFN-γ and IL-17 levels over the non-adjuvanted combinations and control mice (p < 0.05). Results are the mean stimulation index ± S.D. of six mice
per group from three independent experiments.
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diﬀerences in inducing the immune responses by AddaVax may be the
result of the type of antigens used; the mice model, the concentration of
antigen and adjuvant used as well as the route of immunization (Casella
and Mitchell, 2008).
Except for IL-17 production, there was no signiﬁcant diﬀerence in
the immunogenicity and protection between mice vaccinated with
fusion+AddaVax and MUP+AddaVax. The fusion construct was
composed of limited epitopes of MrpA (80 aa), UcaA (71 aa), Pta (192
aa), and linkers (30 aa) (Fig. 1 and Table 1), whereas the MUP com-
bination was the mixture of full-length of MrpA (175 aa), UcaA (180 aa)
and the passenger domain of Pta (524 aa), thus it is notable that the
selected epitopes in fusion could induce the immunogenicity and pro-
tection in the level of antigens used in the combined formulation
(MUP). This noteworthy ﬁnding demonstrates if the B- and T- cells
epitopes of antigens could be correctly selected, they will have the
advantage over vaccines based on the full-length of antigens.
According to the challenge results, all vaccine formulations in the
presence and absence of adjuvant conferred signiﬁcant protection in the
bladder and kidneys of mice that showed the potential of the Pta, MrpA
and UcaA antigens in fusion and non-fusion forms as vaccine candi-
dates. Pellegrino et al. (2003) reported the eﬃcacy of candidates MrpA
and UcaA in kidney protection in S.C. route, whereas Scavone et al.
(2004) showed the signiﬁcant protection of both bladder and kidneys in
mice vaccinated I.N. with MrpA and UcaA. The protection eﬀectiveness
of MrpA expressed in S. typhimurium or L. lactis strains was also ob-
served in mice model (Scavone et al., 2007; Scavone et al., 2011). In
other study, Alamuri et al. (2009) demonstrated that immunization
with Pta coupled with cholera toxin (CT) adjuvant provided signiﬁcant
protection against P. mirabilis UTI, especially in the upper urinary tract.
Among the tested candidates, fusion admixed with AddaVax showed
the highest protection in the bladder and kidney against P. mirabilis.
Interestingly, the protection level of fusion+AddaVax in the present
study was in the levels of protection of fusion+MPL combination in
our previous study. The signiﬁcant protection of mice injected with
Fusion+AddaVax could be attributed to the high mucosal and sys-
temic responses (Russo et al., 2003). It is also possible that the elevated
cytokines (CMI) played a critical role in the protection of this mice
group (Alteri et al., 2009). The ﬁndings also showed a direct relation-
ship between the reduction of bacterial load within the bladders and
decrease of infection in the kidneys, thus the reduction of bacterial load
in bladder may result in kidney protection. Interestingly, the protection
eﬃcacy in mice vaccinated with MUP+AddaVax was lower than
fusion alone, whereas this mice group revealed higher immunogenicity
than mice injected with fusion alone. The reason for this discrepancy
could be due to the decrease in IL-17 levels by the MUP+AddaVax or
other immunological mechanisms that require further studies.
5. Conclusions
In the present study, novel multi-peptide vaccine based on the im-
portant epitopes of MrpA, UcaA and Pta was constructed and its ef-
fectiveness was evaluated with and without AddaVax as adjuvant. By
comparing the results of this study with the results of previous vaccines,
it was concluded that the AddaVax-based vaccine combinations had
signiﬁcant eﬃcacy against P. mirabilis, and further studies are needed to
present the promising vaccine combinations as the potential candidates
against P. mirabilis. Furthermore, the ﬁndings of the present study
suggest that AddaVax can be a good alternative for traditional ad-
juvants especially for vaccine candidates against UTI pathogens.
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